Comparative Pharmacology
Head-to-head clinical analysis: AMITRIL versus TRIMIPRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITRIL versus TRIMIPRAMINE MALEATE.
AMITRIL vs TRIMIPRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, thereby increasing their synaptic concentrations. It also blocks histamine H1, alpha-1 adrenergic, and muscarinic receptors.
Inhibits reuptake of norepinephrine and serotonin, with moderate anticholinergic, sedative, and antihistaminergic effects.
Adults: Initial 25 mg PO once daily at bedtime, increase by 25 mg every 3-7 days as tolerated to typical maintenance 75-150 mg/day PO divided doses or single dose at bedtime. Maximum 300 mg/day.
25-150 mg orally once daily at bedtime, starting at 25 mg and titrating up by 25 mg every 3-4 days.
None Documented
None Documented
Terminal elimination half-life: 15–25 hours (mean 20 h); may extend to >40 h in elderly or hepatic impairment.
Terminal elimination half-life: 22–32 hours (mean 24 hours); in elderly or hepatic impairment, may extend to 40–50 hours requiring dose adjustment.
Renal: ~70% as metabolites, <5% unchanged; fecal: ~30% via bile.
Renal: ~70% as metabolites (unchanged <5%); fecal: ~30% via biliary excretion.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant